Pipeline Overview

Blend’s pipeline exemplifies the company’s Pentarin™ platform that creates novel treatments designed to improve the effectiveness of cancer therapies for solid tumors.

The company’s lead Pentarin drug candidate is PEN-221 designed to treat patients with neuroendocrine cancers and small cell lung cancer that overexpress the somatostatin receptor. PEN-221 is expected to enter the clinic in mid-2016.

Blend is advancing our pipeline with a focus on cell surface and deep tumor targets in solid tumors and has generated data demonstrating that Pentarins will be effective as a new and innovative class of biologic drug conjugates.

blend pipeline

[Read more about BTP-114]